Tag Archives: atypical antipsychotics

Drugging the Vulnerable: Atypical Antipsychotics in Children and the Elderly

Pharmaceutical companies have recently paid out the largest legal settlements in U.S. history — including the largest criminal fines ever imposed on corporations — for illegally marketing antipsychotic drugs. The payouts totaled more than $5 billion. But the worst costs of the drugs are being borne by the most vulnerable patients: children and teens in psychiatric hospitals, foster care and juvenile prisons, as well as elderly people in nursing homes. They are medicated for conditions for which the drugs haven’t been proven safe or effective — in some cases, with death known as a known possible outcome.

The benefit for drug companies is cold profit. Antipsychotics bring in some $14 billion a year. So-called “atypical” or “second-generation” antipsychotics like Geodon, Zyprexa, Seroquel, Abilify and Risperdal rake in more money than any other class of medication on the market and, dollar for dollar, they are the biggest selling drugs in America.

Science Daily: Almost 1/3 of U.S. nursing home residents received antipsychotic drugs as chemical restraints

Science Daily is reporting that a study shows that newly admitted elderly patients to nursing homes have a higher rate of being prescribed antipsychotic drugs than in previous years. This study found that in 2007, almost one-third of U.S. nursing home residents received antipsychotic drugs. The FDA has issued a warning that there is a great risk of death among older adults with dementia who are taking these agents to control behavioral symptoms.

Pharma Funded FDA’s Christmas Present to Drug Companies: Approving use of deadly antipsychotic drugs for kids

Many states have sued over the cost of atypical antipsychotic drugs, especially the cost of treating the diabetes and metabolic disorders they cause, which has decimated Medicaid budgets. Yet now the FDA gives pharma the Christmas present of approving Seroquel and Zyprexa for children and hence, Medicaid reimbursement even as its own Division of Pharmacovigilance (DPV) reported a “a direct association between adverse metabolic effects of treatment with atypical antipsychotics” and children!